COMIRNATY (Pfizer Australia Pty Ltd)
Product name
COMIRNATY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
44 (255 working days)
Active ingredients
SARS-CoV-2 spike protein (mRNA) LP.8.1
Registration type
NCE/ NBE
Indication
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 6 months of age and older.
The use of this vaccine should be in accordance with official recommendations.